2012
DOI: 10.1016/j.jval.2012.08.1397 View full text |Buy / Rent full text
|
|

Abstract: analysis, showed 89.2% of iterations favored denosumab. CONCLUSIONS: Denosumab was cost-effective over zoledronate from the private health care setting perspective in Brazil, adding gains in benefits at a lower cost in preventing osteoporotic fractures in postmenopausal women. OBJECTIVES:To explore the cost-utility of adding tocilizumab (TCZ) monotherapy to current monotherapy treatment sequences in moderate/severe adult rheumatoid arthritis (RA) patients with inadequate response to one or more disease-modifyi… Show more

Help me understand this report

Search citation statements

Order By: Relevance
Select...
1
0
1
0

Year Published

2015
2015
2015
2015

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

0
1
0
Order By: Relevance
“…Nonetheless, TCZ's favorable cost-effectiveness (from €13,220/QALY to €36,900/QALY) as a monotherapy Fig. 2 Cost-effectiveness scatterplot was demonstrated by findings of economic evaluations performed in the USA [40], Turkey [41], Spain [42], Portugal [43], Scotland [44], UK [45] and Romania [46]. A UK-based study [47], using a similar research design and model, reports an ICER of £7,289/QALY for TCZ first line and an ICER of £11,400/QALY for TCZ second line, leading to the notion that the current study's findings could be regarded rather conservative.…”
Section: Discussionmentioning
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1.2b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 7 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 130,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…Nonetheless, TCZ's favorable cost-effectiveness (from €13,220/QALY to €36,900/QALY) as a monotherapy Fig. 2 Cost-effectiveness scatterplot was demonstrated by findings of economic evaluations performed in the USA [40], Turkey [41], Spain [42], Portugal [43], Scotland [44], UK [45] and Romania [46]. A UK-based study [47], using a similar research design and model, reports an ICER of £7,289/QALY for TCZ first line and an ICER of £11,400/QALY for TCZ second line, leading to the notion that the current study's findings could be regarded rather conservative.…”
Section: Discussionmentioning